GenSight Biologics Reports Full Year 2016 Financial Results

Paris, France, March 13, 2017 – GenSight Biologics (Euronext: SIGHT, ISIN: FR0013183985, PEA-PME eligible), a biopharma company that discovers and develops innovative gene therapies for neurodegenerative retinal diseases and diseases of the central nervous system, today announced its full year 2016 financial results.

Please find the full PDF press release attached.

Contacts

GenSight Biologics Thomas Gidoin Chief Financial Officer ir@gensight-biologics.com +33 (0)1 76 21 72 20

NewCap Investor Relations Florent Alba gensight@newcap.eu +33 (0)1 44 71 98 55

Rooney Partners Media Relations Marion Janic mjanic@rooneyco.com +1-212-223-4017

---

Source: GenSight Biologics